Tags

Type your tag names separated by a space and hit enter

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.
Clin Lymphoma Myeloma Leuk. 2020 11; 20(11):774-776.CL

Links

PMC Free PDF

Authors+Show Affiliations

Yasuda H
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. Electronic address: hyasuda@juntendo.ac.jp.
Tsukune Y
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Watanabe N
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Sugimoto K
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Uchimura A
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Tateyama M
Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Miyashita Y
Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Ochi Y
Department of Respiratory Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Komatsu N
Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

MeSH

Antibodies, NeutralizingAntibodies, ViralAntineoplastic Agents, ImmunologicalBetacoronavirusCOVID-19Chronic DiseaseCoronavirus InfectionsFemaleHumansLungLymphoma, FollicularMiddle AgedPandemicsPneumonia, ViralRituximabSARS-CoV-2Tomography, X-Ray Computed

Pub Type(s)

Case Reports

Language

eng

PubMed ID

32933879

Citation

Yasuda, Hajime, et al. "Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma." Clinical Lymphoma, Myeloma & Leukemia, vol. 20, no. 11, 2020, pp. 774-776.
Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774-776.
Yasuda, H., Tsukune, Y., Watanabe, N., Sugimoto, K., Uchimura, A., Tateyama, M., Miyashita, Y., Ochi, Y., & Komatsu, N. (2020). Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clinical Lymphoma, Myeloma & Leukemia, 20(11), 774-776. https://doi.org/10.1016/j.clml.2020.08.017
Yasuda H, et al. Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(11):774-776. PubMed PMID: 32933879.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma. AU - Yasuda,Hajime, AU - Tsukune,Yutaka, AU - Watanabe,Naoki, AU - Sugimoto,Kazuya, AU - Uchimura,Ayana, AU - Tateyama,Misa, AU - Miyashita,Yosuke, AU - Ochi,Yusuke, AU - Komatsu,Norio, Y1 - 2020/08/22/ PY - 2020/07/08/received PY - 2020/08/08/revised PY - 2020/08/17/accepted PY - 2020/9/17/pubmed PY - 2020/11/18/medline PY - 2020/9/16/entrez KW - Atypical presentation KW - CHOP KW - Coronavirus KW - Hematological malignancy KW - Obinutuzumab SP - 774 EP - 776 JF - Clinical lymphoma, myeloma & leukemia JO - Clin Lymphoma Myeloma Leuk VL - 20 IS - 11 SN - 2152-2669 UR - https://www.unboundmedicine.com/medline/citation/32933879/Persistent_COVID_19_Pneumonia_and_Failure_to_Develop_Anti_SARS_CoV_2_Antibodies_During_Rituximab_Maintenance_Therapy_for_Follicular_Lymphoma_ DB - PRIME DP - Unbound Medicine ER -